GraMedica

What GraMedica does

GraMedica (legal entity: Graham Medical Technologies, LLC) is a Michigan-based medical device company founded in 2004 by a foot and ankle surgeon to address a structural treatment gap in flatfoot and joint misalignment above the heel. The company's flagship technology is the HyProCure® titanium stent, a sinus tarsi implant that provides extra-osseous talotarsal stabilization (EOTTS) as a motion-preserving, reversible alternative to orthotics management and bone-cutting fusion surgery. HyProCure® II, the second-generation device, is FDA-cleared under K042030 and K142534 and is supported by 109 independent peer-reviewed publications spanning 20+ years. The product portfolio also includes the Opti-Toe® hammertoe implant, the Osteo-Wedge® bone-wedge system, and a complete HyProCure® II instrument set (HYPIIINSTRAY) with proprietary instruments such as Graham Decompression Scissors.

GraMedica manufactures 100% of its products in the United States under ISO 13485 quality systems and holds CE MDR, Health Canada, and TAA compliance, in addition to FDA clearance and Premier Inc. Breakthrough Technology designation. The company distributes commercially in 46 countries through direct surgeon engagement (surgeon locator program), regional distribution partnerships, strategic licensing, and white-label/OEM arrangements. More than 100,000 patients have been treated with HyProCure® implants cumulatively. The company is led by CEO Joe Monroe and operates with 11-50 employees from its headquarters at 236 Mill Street, Rochester, Michigan. Revenue is generated through one-time hardware sales of implants and instruments to surgeons and hospitals, supplemented by licensing royalties and OEM/wholesale arrangements; pricing for the HyProCure® implant is not publicly disclosed and is handled through quote-based procurement channels.

The company's go-to-market combines evidence-based clinical marketing to surgeons and podiatrists with a structured three-tier partnership program for international expansion: regional distribution for distributors with surgeon relationships, strategic licensing for entrants to the EOTTS category, and white-label/OEM manufacturing for foot and ankle brands. The competitive positioning emphasizes clinical outcomes (98.96% implant success at 8 years per Fu et al. 2025; 58.92% radiographic correction vs. 3.20% with orthotics per Steber & Kolodziej 2015) and procedural advantages (under 20 minutes, outpatient under local anesthesia, walking in 3-4 days, fully reversible) that distinguish it from both conservative orthotic management and irreversible fusion surgery.

Name

GraMedica

Legal name

Graham Medical Technologies, LLC

Website

https://gramedica.com

Company type

Private

Founded year

2004

Operating status

Operating

Headcount range

11–50 employees

Short description

GraMedica is a Michigan-based medical device company that develops and manufactures FDA-cleared titanium implants, led by the HyProCure® sinus tarsi stent, for foot and ankle surgeons and podiatrists treating structural misalignment. It distributes across 46 countries via direct sales, regional partners, and licensing.

Ownership category

akta.pro rank

Product category

Foot and Ankle Orthopedic Implants

NAICS

Surgical Appliance and Supplies Manufacturing (339113), Surgical and Medical Instrument Manufacturing (339112)

SIC

Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)

akta.pro primary industry

Orthopedic Joint Reconstruction Implants (Hip/Knee/Shoulder/Elbow/Ankle) (HLAHAEAA)

akta.pro secondary industry

Orthopedic Trauma & Extremities Fixation (Plates/Screws/Nails/External Fixation) (HLAHAEAB)

Keywords

• Foot and ankle implants
• Orthopedic medical devices
• Titanium surgical implants
• EOTTS devices
• Sinus tarsi stents

Headquarters

HQ city

Macomb

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Medical Device Sales - Implants: Sale of HyProCure® titanium stents and related surgical implants (Opti-Toe®, Osteo-Wedge®) to surgeons and hospitals. Revenue is generated through one-time device sales for surgical procedures.
2. Surgical Instruments and Procedural Sets: Sale of surgical instruments including Stevens Tenotomy Scissors, Graham Decompression Scissors, General Forceps, and complete HyProCure® II Instrument Sets (HYPIIINSTRAY) for foot and ankle surgical practices.
3. Licensing and OEM Revenue: Strategic licensing of FDA-cleared, patent-protected EOTTS platform to strategics; white-label and OEM arrangements for foot and ankle brands under their own mark.
4. Regional Distribution Partnerships: Regional distribution partnerships where GraMedica supplies the category, training, and evidence while distributors provide surgeon relationships and territory coverage across 46 countries.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels4 records

Core offering

GraMedica manufactures and sells FDA-cleared titanium medical implants for foot and ankle surgery, centered on the HyProCure® Type II extra-osseous talotarsal stabilization (EOTTS) device. The company also offers complementary foot and ankle implants (Opti-Toe®, Osteo-Wedge®) and a full line of surgical instruments and procedural instrument sets used by foot and ankle surgeons and podiatrists. Products are sold to surgeons, hospitals, regional distributors, and strategic partners under licensing and white-label arrangements.

Product overview

GraMedica offers a portfolio of foot and ankle medical devices centered on the HyProCure® platform. The flagship product is the HyProCure® II titanium stent (second generation), an extra-osseous talotarsal stabilization device for correcting foot misalignment. The portfolio includes the original HyProCure® I generation, complementary implants (Opti-Toe® for hammertoe correction, Osteo-Wedge® for osteotomy), specialized surgical instruments (Stevens Tenotomy Scissors, Graham Decompression Scissors, General Forceps), and complete procedural instrument sets. All products are FDA-cleared, ISO 13485-manufactured, and eligible under TAA for federal procurement.

Differentiator

Problem solved

Functional benefit

Brands

• HyProCure®: Titanium implant that corrects misalignment internally by stabilizing the joint above the foot. Second-generation geometry with dramatically reduced profile. FDA-cleared K042030 and K142534. Clinical designation: Type II extra-osseous talotarsal stabilization (EOTTS), placed in the sinus tarsi.
• Opti-Toe®
• Osteo-Wedge®
• HyProCure® II Instrument Set

Products and services

• HyProCure® II Second-generation titanium implant that corrects foot misalignment by stabilizing the joint above the foot through sinus tarsi placement. FDA-cleared (K042030 and K142534). Clinical designation: Type II extra-osseous talotarsal stabilization (EOTTS). For foot and ankle surgeons and podiatrists treating adult and pediatric flatfoot/hyperpronation.
• HyProCure® I Original generation titanium stent for extra-osseous talotarsal stabilization (EOTTS). Commercially distributed in 46 countries as the first generation of the HyProCure® platform. For foot and ankle surgeons treating structural foot misalignment.
• Opti-Toe® Hammertoe correction implant designed for toe deformity correction procedures. For foot and ankle surgeons performing hammertoe surgical repair.
• Osteo-Wedge® Bone-wedge system designed for precise osteotomy procedures in foot and ankle surgery. For foot and ankle surgeons performing corrective bone procedures.
• HyProCure® II Instrument Set Full procedural tray (catalog number HYPIIINSTRAY) containing all instruments needed for HyProCure® II implantation procedures. For foot and ankle surgeons and surgical facilities performing EOTTS implantation.
• Stevens Tenotomy Scissors Precision tenotomy scissors designed for fine tissue plane dissection during surgical procedures. For foot and ankle surgeons and other surgical specialists.
• Graham Decompression Scissors Signature decompression scissors designed for sinus tarsi preparation during HyProCure® procedures. For foot and ankle surgeons performing EOTTS implantation.
• General Forceps 360° forceps set designed for everyday tissue handling during foot and ankle surgical procedures. For foot and ankle surgeons and surgical staff.

Quantifiable outcome

• 98.96% implant success rate at 8 years (Fu et al., 2025, Orthop Surg)
• +5 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Three partnerships are on record, tiered core.

• Regional Distribution PartnerscoreChannel Partner/ Reseller/ DistributorRegional distributors with surgeon relationships and territory depth. GraMedica supplies the category, training, and evidence while distributors provide market access. Partners gain a defensible product line their competitors cannot source.
• Strategic Licensing PartnerscoreStrategic or Co-development PartnerStrategic partners entering or consolidating the EOTTS category. GraMedica provides an FDA-cleared, patent-protected platform; partners bring scale, sales force, and hospital contracts. Skips a decade of build, clinical, and clearance work.
• White-Label/OEM PartnerscoreOEM/ Whitelabel/ Licensing PartnerFoot and ankle brands that want to own a Type II line under their own mark. GraMedica provides ISO 13485 US manufacturing and the only FDA-cleared device in the category. Brand grows; capacity stays full.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Tyber Medical: Foot-and-ankle and upper-extremity orthopedic implant company offering plating and screw systems as well as private-label/OEM capabilities. Comparable to GraMedica in its OEM/channel model and foot-and-ankle focus.
• Paragon 28: Foot-and-ankle-focused orthopedic implant company with a broad portfolio of plates, screws, and soft-tissue products. Comparable to GraMedica as a specialist serving foot-and-ankle surgeons with procedural solutions and dedicated surgeon education.
• Treace Medical Concepts: Public foot-and-ankle implant company focused on the Lapiplasty procedure for bunion correction. Directly comparable to GraMedica as a focused specialist in foot-and-ankle orthopedic implants with proprietary procedural technology and surgeon-training-driven adoption.
• Vilex: Foot-and-ankle implant and instrument manufacturer serving orthopedic and podiatric surgeons. Closely comparable to GraMedica in scale, product scope (implants plus instruments), and surgeon-training-driven distribution.
• Additive Orthopaedics: Foot-and-ankle implant company with a focus on 3D-printed and patient-specific solutions. Comparable to GraMedica as a small-cap foot-and-ankle specialist commercializing procedural implant technology through surgeon engagement.
• Extremity Medical: Privately held foot-and-ankle and upper-extremity implant specialist. Comparable to GraMedica in its niche focus, surgeon-training-driven commercial model, and proprietary implant systems for foot-and-ankle reconstruction.

Broad incumbents

• Smith+Nephew: Global medical-device major with sports-medicine and orthopedic-trauma franchises that include foot-and-ankle products. Comparable to GraMedica as a broad incumbent competing in adjacent orthopedic implant categories.
• Arthrex: Large privately held orthopedic and sports-medicine device company with a meaningful foot-and-ankle portfolio. Comparable to GraMedica as a broader incumbent serving the same surgical specialties with overlapping implant and instrument categories.
• Integra LifeSciences: Diversified medical device company with orthopedic, extremity, and tissue-technology franchises including foot-and-ankle. Comparable to GraMedica as a broader incumbent with overlapping extremity implant offerings.
• Wright Medical (Stryker): Foot-and-ankle specialist brand now part of Stryker, with a deep portfolio of extremity implants. Comparable to GraMedica as a larger incumbent in the same clinical specialty, offering overlapping foot-and-ankle solutions.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/gramedica
• Facebookfacebook.com/gramedicafans

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about GraMedica